Page last updated: 2024-12-10

1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, **1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinecarboxamide**, is a complex organic molecule with a specific structure. It is important for research because it exhibits **potential biological activity**.

Here's a breakdown of its components and potential significance:

**Structure:**

* **Benzothiadiazole (BTD):** A heterocyclic ring system known for its ability to absorb light in the UV-Vis range. This characteristic makes it useful in applications like dyes, pigments, and potentially in photoactive materials.
* **Sulfonyl Group:** A sulfur-containing group that often contributes to drug-like properties, including binding to proteins.
* **Piperidinecarboxamide:** A cyclic amine derivative that can interact with biological targets like enzymes and receptors.
* **3,4-Dimethoxyphenyl:** A substituted aromatic ring containing two methoxy groups (CH3O-). This group can influence the compound's solubility and interaction with biological systems.

**Potential Significance in Research:**

* **Drug Development:** This compound could potentially act as a **lead compound** for developing new drugs with therapeutic applications. The presence of a benzothiadiazole ring and a sulfonyl group suggests potential for targeting enzymes or receptors involved in various biological processes.
* **Materials Science:** The benzothiadiazole moiety might contribute to the compound's ability to absorb and emit light, potentially making it useful in **optoelectronic materials**, such as solar cells or light-emitting diodes.
* **Biological Studies:** The compound's structure and functional groups could be of interest in studying the interaction of organic molecules with biological systems. This might provide insights into **protein-ligand interactions**, **enzyme kinetics**, or **drug delivery mechanisms**.

**Important Note:** The specific biological activity and potential applications of this compound would depend on its detailed chemical properties and experimental testing. Without further information, it is impossible to determine its exact significance.

**To get a more comprehensive understanding of the compound's importance, you would need to research:**

* **Its specific biological activity:** Has it been tested for any particular therapeutic effect?
* **Its synthesis and characterization:** How was it prepared and what are its physical and chemical properties?
* **Its interaction with biological systems:** Does it bind to any specific proteins or receptors?
* **Its potential applications:** Is it being explored for any particular therapeutic or materials science use?

Researchers studying this compound are likely interested in its potential as a drug candidate or as a component in new materials with unique properties.

Cross-References

ID SourceID
PubMed CID3242258
CHEMBL ID1523996
CHEBI ID112721

Synonyms (12)

Synonym
AKOS001805989
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-4-carboxamide
MLS000091777
smr000026324
MLS000876883
CHEBI:112721
STK853905
HMS2333I14
CHEMBL1523996
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinecarboxamide
Q27192836
1-(2,1,3-benzothiadiazole-4-sulfonyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-4-carboxamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency31.62280.044717.8581100.0000AID485341
TDP1 proteinHomo sapiens (human)Potency10.32250.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
DNA polymerase betaHomo sapiens (human)Potency0.44670.022421.010289.1251AID485314
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency14.12540.00419.962528.1838AID2675
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]